InControl, EP MedSystems ink atrial defibrillation catheter agreement.
This article was originally published in The Gray Sheet
INCONTROL/EP MEDSYSTEMS ATRIAL DEFIBRILLATION CATHETER AGREEMENT involves a supply/distribution exchange of rights to two developmental atrial defibrillation devices, the firms announced Aug. 15. Under the agreement, InControl obtains European marketing rights to EP Medsystems' Atrial Low Energy Reversion Therapy (ALERT) atrial defibrillation catheter; in return, EP Medsystems will manufacture InControl's temporary atrial defibrillation catheter, tentatively dubbed the TADcath.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.